Agoracom Blog Home

Archive for the ‘Tetra Brio-Pharma Inc.’ Category

« Older Entries
Newer Entries »

Tetra Bio-Pharma Inc. Announces Binding Letter of Intent for JV Co-Development and Commercialization of Health Care Products Containing Cannabinoids also Closes Private Placement $TBP.ca

Posted by AGORACOM-JC at 9:03 AM on Tuesday, January 10th, 2017

Tbp large

  • Entered into a binding letter of intent to form a joint venture with Ford’s Family Pharmacy and Wellness Center (“FFP”) in Moncton, New Brunswick
  • Primary objective of this venture is the development and commercialization of cannabinoid-based products for the Canadian health care market with a special focus on CBD and THC-free cannabis products for the USA cosmetic and supplement market

OTTAWA, ONTARIO–(Jan. 10, 2017) – Tetra Bio-Pharma Inc. (“TetraBio“, “TBP“, or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GROPF) through its subsidiary, Agro-Tek Health Inc. (“GTK“), is pleased to announce that it has entered into a binding letter of intent to form a joint venture with Ford’s Family Pharmacy and Wellness Center (“FFP“) in Moncton, New Brunswick. The primary objective of this venture is the development and commercialization of cannabinoid-based products for the Canadian health care market with a special focus on CBD and THC-free cannabis products for the USA cosmetic and supplement market.

About Tetra Bio-Pharma

Tetra Bio-Pharma, through its subsidiaries, is engaged in the development and commercialization of cannabis-based pharmaceuticals and consumer health products. www.tetrabiopharma.com

About Agro-Tek Health

Agro-Tek Health is a subsidiary of Tetra Bio-Pharma Inc. and is focused on commercialization of over the counter consumer goods containing cannabis and other non-controlled medicinal plants.

About Ford’s Family Pharmacy

Ford’s Family Pharmacy and Wellness Center currently holds a Controlled Substance License from Health Canada for the processing, packaging, and distribution of controlled substances. https://www.fordrx.com

Since 1997, Ford’s Family Pharmacy & Wellness Centre has helped clients improve and prolong their health, wellness, and vitality by providing personalized compounding and wellness solutions. Their team consists of: four pharmacists, 14 pharmacy technicians/assistants and two registered nurses. FFP provides innovative solutions to complex medical problems and works with Canadian healthcare providers (including physicians, veterinarians, and dentists) to create well-rounded, comprehensive natural and compounding treatment plans.

To maximize the benefit of this venture, GTK will establish its health care product development and commercialization activities within the province of New Brunswick. New Brunswick is quickly positioning itself as a desired homebase for companies in the cannabis industry and GTK commends the government of New Brunswick for its assistance in establishing this project.

Dr. Peter Ford, Pharm D will work with GTK to develop cannabinoid-based skin care and wellness products for the Canadian retail markets. This joint venture will allow GTK to develop a portfolio of innovative CBD-based products for patient self-care in addition to CBD and THC-free products for the USA cosmetic and supplement market.

According to Mr. André Rancourt, Chief Executive Officer, “These products will allow GTK to commercialize cannabis-derived products for the Canadian and USA wellness market in preparation for the unveiling of Canada’s new cannabis regulations.”

Dr. Ford will also assist TetraBio with its ongoing NSERC Engage partnership grant with McGill University (see press release from October 19, 2016). Dr. Ford’s expertise will also be used for the development of the PPP001 dried cannabis pellets for upcoming phase 1 clinical trials. “The partnerships with McGill University and Dr. Ford are in line with the Company’s vision to expand its commercial operations focused on the development and sale of cannabis-derived supplements and retail products for the North American market,” commented Mr. Rancourt.

Dr. Guy Chamberland, M.Sc., Ph.D., Chief Science Officer, commented, “Ford’s Family Pharmacy and Wellness Center currently holds a Controlled Substance License from Health Canada for the processing, packaging, and distribution of controlled substances. Working with Dr. Ford will allow TBP to adhere to current regulations relating to controlled substances including cannabis. This resource allows TBP to further its ongoing projects while remaining compliant with Canadian and US narcotics regulations.” He also stated, “Dr. Ford is a renowned expert in wellness and a highly-experienced formulator and this joint venture will help the Company bring cutting edge cannabis-based health and wellness products to patients and consumers in a timely and cost effective manner.”

This project will be funded via current working capital and the previously announced NSREC research grant in collaboration with McGill University.

Closing of Non-brokered Private Placement

The Company is also pleased to announce that, on December 30, 2016, it closed a non-brokered private placement of 2,395,500 units at a price of $0.20 per unit for aggregate gross proceeds of $479,100. Each unit consists of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.26 per share for a period of twelve months expiring December 30, 2017.

The securities issued pursuant to the private placement are subject to a four-month hold period from the closing date and subject to all necessary regulatory approvals, including the approval of the Exchange.

The proceeds of the private placement will be used to pursue commercialization projects in 2017 and increase scientific staff.

In Other News

Tetra Bio-Pharma is also pleased to announce that, effective December 16, 2016, TBP has been added to the Canadian Securities Exchange composite index. The index is comprised of listed companies that meet market capitalization, trading, and seasoning criteria established by the exchange.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
343-689-0714

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Scientific Officer
343-689-0714
www.tetrabiopharma.com

Tags: , , ,
Posted in Featured, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Inc. Announces Binding Letter of Intent for JV Co-Development and Commercialization of Health Care Products Containing Cannabinoids also Closes Private Placement $TBP.ca

Aphria Makes $1,000,000 Investment in Tetra Bio-Pharma via Private Placement to Fund PhytoPain Pharma Clinical Trials $TBP.ca

Posted by AGORACOM-JC at 9:29 AM on Tuesday, December 6th, 2016

Tbp large

  • Conducting non-brokered private placement with Aphria Inc. (TSX VENTURE:APH)(OTCQB:APHQF) of 5,000,000 units at a price of $0.20 per unit for aggregate gross proceeds of $1,000,000
  • Proceeds of the private placement will be used to initiate clinical trials in PhytoPain Pharma Inc

OTTAWA, ONTARIO–(Dec. 6, 2016) – Tetra Bio-Pharma Inc. (“Tetra Bio” or “the Company”) (CSE:TBP)(CSE:TBP.CN) and (OTC PINK:GRPOF) is conducting a non-brokered private placement with Aphria Inc. (TSX VENTURE:APH)(OTCQB:APHQF) of 5,000,000 units at a price of $0.20 per unit for aggregate gross proceeds of $1,000,000. Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share of the Company at a price of $0.26 per share for a period of 3 years following the closing date. The warrants are subject to an accelerated expiry if the Company’s shares trade above $0.45 for thirty (30) consecutive trading days then the warrants will expire in 30 days if not exercised.

The private placement closed on December 5, 2016.

Completion of the private placement is subject to the receipt of all necessary regulatory approvals, including the approval of the Exchange.

The securities issued pursuant to the private placement will be subject to a four-month hold period from the closing date.

The proceeds of the private placement will be used to initiate clinical trials in PhytoPain Pharma Inc.

“Obtaining an investment from one of Canada’s leading cannabis producers re-enforces the value of the research and development being conducted by the science team at Tetra Bio-Pharma lead by Chief Science Officer, Dr. Guy Chamberland,” commented Ryan Brown, Co-Founder/VP Business Development.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications

Tetra Bio-Pharma Inc.
André Audet
Executive Chairman

[email protected]
(613) 421-8402

 

Tags: , ,
Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Aphria Makes $1,000,000 Investment in Tetra Bio-Pharma via Private Placement to Fund PhytoPain Pharma Clinical Trials $TBP.ca

Tetra Bio-Pharma Provides USA Regulatory Update for its Cannabis Inhalation Product PPP001 $TBP.ca

Posted by AGORACOM-JC at 9:04 AM on Wednesday, November 23rd, 2016

Tbp large

  • Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit
  • FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.

OTTAWA, ONTARIO–(Nov. 23, 2016) – PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF), is a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that the development of its smoked marijuana prescription drug is on schedule.

The Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration (“FDA“) had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit. The FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research (“CDER“) as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.

The Company previously announced that it received a pre-IND (Investigational New Drug) acknowledgement and meeting request granted letter from the US FDA. This week, the company is submitting the information package required by FDA for the Type B pre-IND meeting in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research. According to Dr. G. Chamberland, Chief Science Officer, “As per FDA policies, the pre-IND information package is submitted to obtain guidance from FDA on the product development and marketing requirements for the smoked marijuana prescription drug combination product”. Dr. Chamberland further commented that this regulatory filing is part of PPP’s dedication to the commercialization of marijuana as a prescription controlled drug and the corporation’s plan to seek reimbursement by insurers for patients.

The Company has been working with Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy human subjects. PPP is using the services of Algorithme Pharma based on its experience and expertise in the conduct of clinical trials for the pharmaceutical industry. Later this week the project team will be submitting the Phase I clinical protocol, and related documents, to the Institutional Review Board for review. If approved, Algorithme Pharma will subsequently submit the Clinical Trial Application to the Therapeutic Products Directorate of Health Canada for approval. In parallel, Algorithme Pharma will submit an application for exemption under section 56 of the Controlled Drugs and Substances Act for its planned research on healthy subjects.

The Company stated that, subsequent to a request for classification to the Medical Devices Bureau, Health Canada, the PPP001-titanium pipe that will be used in the clinical trial is a Class I medical device. Dr. Chamberland commented: “As a Class I medical device, the PPP001-titanium pipe does not require approval for use in the clinical trial”.

About PPP001-kit product

PPP001-kit product will be sold as two separate products packaged together in a single package and is comprised of the drug PPP001 and the device PPP001-titanium pipe. The drug component and device component will be linked together by the labelling of each component.

The product PPP001-kit, once approved, could be sold in pharmacies containing the prescription controlled drug PPP001, in a blister pack, and the PPP-titanium pipe device that will be used to generate the smoke to deliver the active ingredients by inhalation.

PPP001 drug pellet blisters and a fully assembled PPP-titanium pipe for combustion and inhalation of the generated smoke are required for therapy with PPP001 and are provided in the PPP001-kit.

Each blister of PPP001 drug pellet contains marijuana with a standardized amount of delta-9-tetrahydrocannibinol and cannibidiol. A single PPP001 drug pellet is pushed out of the blister by the patient and inserted into the PPP-titanium pipe.

In Other News:

The Company has received $227,738 in exercised warrants for November 2016.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Ryan Brown – VP Business Development and Communications
Andre Audet – Executive Chairman
Dr. Guy Chamberland – Chief Scientific Officer
(613) 421-8402

Tags: , , , , ,
Posted in Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Provides USA Regulatory Update for its Cannabis Inhalation Product PPP001 $TBP.ca

Pot stocks soar as legal weed seen surviving Trudeau tax $MCOA.us $TBP.ca

Posted by AGORACOM-JC at 8:54 AM on Thursday, November 17th, 2016

GREG QUINN

Bloomberg News

Published

Last updated

  • Canadian marijuana stocks surged after the head of the country’s biggest producer said his company could cope with taxes as high as 25 per cent, extending a rally that began in the summer with the prospect of legal recreational use.
  • Bruce Linton, chief executive officer of Canopy Growth Corp., says Prime Minister Justin Trudeau’s government will probably choose to control the distribution of legal recreational marijuana through government-run outlets such as liquor stores. A task force is due to report this month on how Canada can build a legal weed market.

“We can probably carry a tax burden of 25 per cent or so and end up in the consumer hands on a still cost-competitive basis, with a superior product,” Mr. Linton said Monday in an interview at Bloomberg’s Ottawa newsroom.

Canopy, based in Smith Falls, Ont., became the first marijuana producer to trade on a major North American stock exchange when it graduated to the Toronto Stock Exchange in July. It became the first publicly traded Canadian producer of the drug in 2014.

The company’s share price more than doubled this month, bringing its market value past $1.6-billion, on better-than-expected earnings and after U.S. elections widened the scope for legal marijuana. The stock was up as much as 33 per cent Wednesday, and was up 5.4 per cent to $14.17 as of 2:10 p.m. Toronto time.

Emerald Health Therapeutics Inc. jumped as much as 62 per cent intraday, and Aurora Cannabis Inc. climbed as much as 50 per cent.

“Anytime there’s more media attention to the sector it brings in more investors,” Jason Zandberg, an analyst covering marijuana producers at PI Financial Corp. in Vancouver, said by phone. “We found that there’s been a lot of interest from U.S. investors. They have a difficulty in investing in the sector given the weird framework that’s in the U.S. where it’s illegal at a federal level.”

Canopy already produces medical marijuana under an existing legal regime. Mr. Linton says the company, which operates out of a former chocolate factory, can shift production to serve the recreational market when Mr. Trudeau’s government makes that legal.

Part of the appeal of the legal variety will be its quality control, Mr. Linton says. “When it’s lawfully available from a reliable supply chain, which we know we can trust and believe in, there are a lot of people who might discontinue the use of say a glass of wine or a beer and try this.”

Canopy can also generate new formulations of medical marijuana to sell through pharmacies as legalization moves ahead, Linton said. Loblaw Cos., owner of the Shoppers Drug Mart pharmacy chain, said Wednesday its is engaging with the government to dispense marijuana from stores.

“There’s a lot of advantages for Canadian producers,” Mr. Zandberg said. Linton “pointed out some key points. I find there’s a lot of interesting aspects to this market that aren’t well known and he definitely highlighted a few that have caused a bit of excitement as well.”

Tags: ,
Posted in Marijuana Company of America, Medical Marijuana Stocks, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Pot stocks soar as legal weed seen surviving Trudeau tax $MCOA.us $TBP.ca

Tetra Bio-Pharma Achieves DTC Eligibility in the United States $TBP.ca

Posted by AGORACOM-JC at 8:35 AM on Wednesday, November 16th, 2016

Tbp_large

  • Effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market
  • Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”.

OTTAWA, ONTARIO–(Nov. 16, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF) is pleased to announce that effective November 13, 2016, it has secured Depository Trust Company (DTC) eligibility for its common shares listed on the OTCPINK Market.

Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors.

The Company’s common shares are listed for trading on the OTCPINK, a U.S. based securities trading system, under the symbol “GRPOF”. Tetra Bio-Pharma shares will continue to be traded on the Canadian Stock Exchange under its existing symbol “TBP”.

André Rancourt, Chief Executive Officer, commented, “We’re pleased to announce that our shares have become DTC eligible on the U.S. market and excited to bring our Company to the attention of the investment community in the U.S. We believe that GRPOF offers investors a unique opportunity to invest in a bio pharmaceutical cannabis company before entering clinical trials later this year.

In other company news

Website:

The Company is proud to announce that its website located at www.tetrabiopharma.com is now live. We encourage investors to sign up for news releases and notifications as more information is added to the website.

Industry Participation:

Dr. Guy Chamberland, Chief Scientific Officer and regulatory affairs, and Ryan Brown, co-founder and VP of Business Development, will be presenting at the World of Cannabis business summit in Las Vegas on November 16th 2016. Dr. Chamberland will be presenting as part of “the science of medical cannabis” program while Ryan Brown will be presenting at the “emerging brands investor pitch seminar” more info can be found at www.worldofcannabissummit.com.

Investor Relations:

The Company would like to inform investors that it has engaged Alpha Deal Group LLC, a New York based buy side analyst firm, to perform investor analysis for presentation to its investment network.

As released on November 9, 2016, via CFN (Cannabis Financial Network), the Company has engaged Cannabis Financial Network to increase its visibility in the United States retail investment market.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
Phone: (613) 421-8402

Ryan Brown
Co-founder and Director of Communications
Phone: (613) 421-8402

Andre Audet
Executive Chairman
Phone: (613) 421-8402

Tags: , , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Achieves DTC Eligibility in the United States $TBP.ca

Canada could thrive from marijuana legalization in U.S. states $MCOA.us $TBP.ca

Posted by AGORACOM-JC at 3:52 PM on Thursday, November 10th, 2016
  • Voters in California, Massachusetts and Nevada approved on Tuesday the use of recreational cannabis, joining four other states and Washington, D.C., that have similar laws in place.
  • Florida, North Dakota and Arkansas approved medical marijuana, which would bring the total number of states with such a system to more than two dozen.
By ALEXANDRA POSADZKI The Canadian Press
Thu., Nov. 10, 2016

Canada’s marijuana industry could benefit after at least six states representing twice the population of Canada voted in favour of legalizing the drug, either recreationally or medically.

Voters in California, Massachusetts and Nevada approved on Tuesday the use of recreational cannabis, joining four other states and Washington, D.C., that have similar laws in place.

Florida, North Dakota and Arkansas approved medical marijuana, which would bring the total number of states with such a system to more than two dozen.

Shipping marijuana into the U.S., whether for medical or recreational purposes, is illegal. But the CEO of Privateer Holdings, a U.S.-based private equity firm that focuses on investing in the marijuana sector, says he expects Canadian producers will enter into partnerships and joint ventures with their neighbours to the south following the referendums.

“I think you’ll see Canadian companies jump at the opportunity to expand their operations and brands into the United States,” says Brendan Kennedy, whose firm owns Nanaimo, B.C.-based licensed producer Tilray.

That could mean everything from participating in the production process to providing consulting services or licensing intellectual property to U.S. producers, Kennedy says.

“There are huge opportunities for Canadian companies, because Canada has the most robust and tightly regulated medical cannabis framework in the world,” he says.

“Both governments and companies around the world are looking to Canada to provide leadership and expertise in this industry.”

People in Montana voted to expand its current medical marijuana regime. In Maine, voters appeared to be inching toward legalizing recreational use, but as of early Thursday, the results were still to close to call.

Presuming all eight states approve their various marijuana initiatives, that could inject $7.4 billion (U.S.) annually into the marijuana market by 2020, Arcview Market Research says. That would open the door to a recreational and medical marijuana market in the U.S. worth $21.2 billion by that same time, according to the research firm.

Alan Gertner, CEO of luxury marijuana brand Tokyo Smoke, says the legalization push means more opportunities for brand licensing deals. His company is already working with partners in Florida and Massachusetts, he said.

“Generally, more legal consumers means more opportunity to build and scale Canadian cannabis brands,” Gertner said in an email.

Canadian companies that build equipment and technology that help grow medical marijuana will also gain access to a larger market, he added.

Cam Battley, executive vice-president of Alberta-based licensed producer Aurora Cannabis Inc., says Canada is home to some of the largest commercial marijuana producers in the world.

Having a federally regulated medical marijuana regime — rather than a piecemeal, state-by-state system like the U.S. — has allowed Canadian marijuana companies to master large-scale, commercial production techniques, says Battley.

“We do have a lot of expertise, and we’ve learned, collectively as a sector, a lot of really important lessons about cultivation and consistent production,” says Battley.

“I think that does give us some advantages and would bode well for partnerships when the time is right.”

Khurram Malik, the cannabis lead at Jacob Capital Management, says the news could also help Canadian marijuana companies secure funding by making investors more comfortable with the sector.

“Most of the money raised up here is from the U.S.,” says Malik. “This legitimizes the concept of cannabis around the world, which is only a positive for the market up here.”

Source: https://www.thestar.com/news/canada/2016/11/10/canada-could-thrive-from-marijuana-legalization-in-us-states.html

Tags: , , ,
Posted in Marijuana Company of America, Medical Marijuana Stocks, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Canada could thrive from marijuana legalization in U.S. states $MCOA.us $TBP.ca

Marijuana wins big on election night $MCOA.us $TBP.ca

Posted by AGORACOM-JC at 8:39 AM on Wednesday, November 9th, 2016


(Linda Davidson/The Washington Post)

  • On the medical side, voters in Florida, North Dakota and Arkansas have approved medical marijuana initiatives
  • separate measure in Montana that would loosen restrictions on an existing medical pot law was leading early Wednesday with only 30 percent of votes counted
  • Reformers were jubilant. “This represents a monumental victory for the marijuana reform movement,” said Ethan Nadelmann, executive director of the Drug Policy Alliance, in a statement. “With California’s leadership now, the end of marijuana prohibition nationally, and even internationally, is fast approaching.”

On the medical side, voters in Florida, North Dakota and Arkansas have approved medical marijuana initiatives. A separate measure in Montana that would loosen restrictions on an existing medical pot law was leading early Wednesday with only 30 percent of votes counted.

Reformers were jubilant. “This represents a monumental victory for the marijuana reform movement,” said Ethan Nadelmann, executive director of the Drug Policy Alliance, in a statement. “With California’s leadership now, the end of marijuana prohibition nationally, and even internationally, is fast approaching.”

How marijuana legalization in Washington, Colorado and Oregon is working out so far
Post)

California has long been seen as a bellwether by both supporters and opponents of marijuana reform. The state is home to about 12 percent of the U.S. population. Given the size of the state’s economy and the economic impact of the marijuana industry there, California’s adoption of legal marijuana could prompt federal authorities to rethink their decades-long prohibition on the use of marijuana.
In a recent interview with Bill Maher, President Obama said that passage of the legalization measures on Tuesday could make the current federal approach to the drug “untenable.”

Still, the likelihood of a Trump White House leaves a lot of uncertainty about the fate of marijuana measures in the next four years. Under Obama, federal authorities largely took a hands-off approach to state-level legalization efforts. But an incoming administration more skeptical of drug reform could easily reverse that approach.

“The prospect of Rudy Giuliani or Chris Christie as attorney general does not bode well,” the Drug Policy Alliance’s Nadelmann said in an interview. “There are various ways in which a hostile White House could trip things up.”

Still, Nadelmann pointed to the success of marijuana measures in the midst of an evident Republican wave as a sign that support for legalization now cuts deeply across party lines. And citing Trump’s often contradictory statements on marijuana and drug use in the past, Nadelmann added that “Donald Trump personally could probably go any which way on this.”

With today’s votes, legal marijuana is also making significant inroads in the Northeast. “Marijuana legalization has arrived on the East Coast,” said Tom Angell of the marijuana reform group Marijuana Majority in an email. “What Colorado and other states have already done is generating revenue, creating jobs and reducing crime, so it’s not surprising that voters in more places are eager to end prohibition.”

Opponents of legalization said they were disappointed by the outcomes. “We were outspent greatly in both California and Massachusetts, so this loss is disappointing, but not wholly unexpected,” said Kevin Sabet of the anti-legalization group Smart Approaches to Marijuana in a statement. “Despite having gained considerable ground in the last few weeks, the out-of-state interests determined to make money off of legalization put in too much money to overcome.”

Votes on medical marijuana in Florida and North Dakota were decisive. Florida’s Amendment 2 passed with 71 percent support, according to the Associated Press. In North Dakota, the AP reports that 64 percent of voters approving of the medical marijuana measure.

[One striking chart shows why pharma companies are fighting legal marijuana]

Two years ago, a medical marijuana measure in Florida earned 58 percent of the vote, just shy of the 60 percent threshold needed for passage. Then, as now, opposition to the measure was fueled by multimillion-dollar donations from Sheldon Adelson, the Las Vegas casino magnate and GOP donor. In 2014 Adelson spent $5.5 million to defeat the measure. This year he’s spent $1.5 million in Florida, and several million more to defeat recreational marijuana measures in other states.

“This is a major tipping point,” said Tom Angell of Florida’s vote. “With Florida’s decision, a majority of states in the U.S. now have laws allowing patients to find relief with medical marijuana, and these protections and programs are no longer concentrated in certain regions of the country like the West and Northeast.”

The victory in North Dakota is something of a surprise as no polling was done on the measure.

The Florida amendment has the potential to be one of the more permissive medical marijuana regimes in the nation. In addition to diseases like HIV, cancer and PTSD, the measure also allows doctors to recommend medical pot for “other debilitating medical conditions of the same kind or class as or comparable to those enumerated, and for which a physician believes that the medical use of marijuana would likely outweigh the potential health risks for a patient.” While the 2014 measure allowed doctors to prescribe marijuana for any illness they believed it would be useful for, the new measure requires they show the illness is severe — though the wording gives physicians considerable leeway in determining which conditions would meet those criteria.

The medical pot measure in North Dakota allows doctors to recommend the drug for a number of severe medical conditions.

With the passage of Amendment 2, Florida will become the first Southern state to enact a robust medical marijuana regime. Medical marijuana is already legal in 25 other states and the District.

Source: https://www.washingtonpost.com/news/wonk/wp/2016/11/08/medical-marijuana-sails-to-victory-in-florida/

Tags: , ,
Posted in Marijuana Company of America, Medical Marijuana Stocks, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Marijuana wins big on election night $MCOA.us $TBP.ca

Tetra Bio-Pharma Enters Into Medical Cannabis Supply Agreement With ACMPR Licensed Producer Aphria Inc. $TBP.ca

Posted by AGORACOM-JC at 8:36 AM on Thursday, November 3rd, 2016

Tbp_large

  • Signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR”) licensed producer Aphria Inc.
  • For the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001

OTTAWA, ONTARIO–(Nov. 3, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it has signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR“) licensed producer Aphria Inc. (“Aphria“) (TSX VENTURE:APH)(OTCQB:APHQF) for the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.

Aphria is a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations.Under this supply agreement with Aphria, PPP shall pursue the development of a prescription controlled inhalation drug product of medical marijuana and seek marketing approval across the world either directly or indirectly through partnerships or licensing agreements. Aphria will be the exclusive supplier of this API to PPP for the development and commercialisation of PP001.

PPP is granted an exclusive, non-transferrable, royalty free, licence to use the API in the development of PPP001. The agreement defines a purchase price during the clinical development and a volume rebate once a target volume is reached.

Both Canadian and USA prescription drug regulations impose rigorous quality systems for the manufacturing of both the API and finished drug product. These requirements include conformance to pharmaceutical Good Manufacturing Practice regulations (“GMP“) as well as demonstrating the ability of the manufacturer to ensure lot-to-lot consistency in the quality and safety of the prescription drug.

Dr. Guy Chamberland, M.Sc., Ph.D., Chief Scientific Officer and Regulatory Affairs, PhytoPain Pharma Inc., commented, “We are very pleased and excited to be working with Aphria in the development of PPP001. Developing prescription botanical based pharmaceuticals requires a high quality GMP system and well-established product specifications to ensure consistent efficacy and ultimately protect the safety of patients. Based on our assessment of Aphria, we are confident that their high quality GMP medical cannabis production facility and impressive quality assurance team will meet or exceed the expectations of both the Canadian and USA prescription drug authorities.”

“With this agreement in place, PPP is now in a solid position to submit its Clinical Trial Application (CTA) for its planned Phase I trial in healthy volunteers. The company is also on track for submitting its Pre-IND Information Package for its upcoming meeting the US FDA,” stated Dr. Chamberland.

“Aphria is excited and proud to be an integral part of advancing the scientific research being led by Dr. Chamberland and the team at Tetra Bio-Pharma. Using our proprietary and high quality medical cannabis blend supported by high calibre research is exactly what professional healthcare practitioners require to gain the confidence to prescribe medical cannabis as a pharmaceutical,” said Vic Neufeld, Chief Executive Officer, Aphria Inc.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Neither the TSX Venture Exchange (the “Exchange”) nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications

Tetra Bio-Pharma Inc.
André Audet
Executive Chairman
(613) 421-8402

Aphria Inc.
Vic Neufeld
1-844-427-4742

Tags: , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Enters Into Medical Cannabis Supply Agreement With ACMPR Licensed Producer Aphria Inc. $TBP.ca

Tetra Bio-Pharma Announces Outcome of its Meeting with its Scientific and Clinical Advisory Board $TBP.ca

Posted by AGORACOM-JC at 1:20 PM on Wednesday, November 2nd, 2016

Tbp_large

  • Held its Scientific and Clinical Advisory Board (“CAB”) meeting on October 29th
  • CAB reviewed the development program of PPP’s inhalation cannabis product PPP001
  • Medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe

OTTAWA, ONTARIO–(Nov. 2, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it held its Scientific and Clinical Advisory Board (“CAB“) meeting on October 29th. The CAB reviewed the development program of PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.

The Board, which is comprised of experts in clinical research, pain management as well as cancer, and neurological product drug development (ref: news release August 26, 2016), met to review and discuss the development program to date, the study design of the Phase I trial and the overall clinical development plan of PPP001. This included the exclusion and inclusion criteria of the proposed Phase I trial, the Phase 1a and 1b dosing scheme, and the pharmacokinetic and pharmacodynamic assessments. The CAB also examined the clinical rationale for the selection of the delta-9-tetrahydrocannibinol (THC) and Cannabidiol (CBD) dose levels for use in PPP001.

The CAB also reviewed the salient elements of future PPP’s Phase II and III clinical trials for the development of PPP001 in various medical conditions, including the use of medical marijuana as a second or third line therapy for cancer and HIV patients with uncontrolled pain. The CAB reports directly to the Board of Directors of the Company and will be submitting a report on the outcome of the CAB meeting in the near future.

Currently, there is only limited safety or efficacy information, if any, derived from well-controlled clinical trials available to physicians to adequately assess the benefits and risks of prescribing medical marijuana. Dr. Luc Vachon, President of the CAB commented: ²the members of the CAB are very pleased and excited to be participating in a full pharmaceutical approach on the development of medical marijuana as a prescription drug. The members expressed that the clinical development plan used by PPP – supported by a formal regulatory path – will help generate the type of clinical information required by physicians.²

“This team of scientific and clinical experts provided us with excellent guidance on the development program. We are pleased to recommend to the Board of Directors that PPP is ready to submit the Clinical Trial Application (CTA) for the conduct of its Phase I trial in healthy human volunteers,” stated Dr. Chamberland, Chief Scientific Officer and Regulatory Affairs.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer
(613) 421-8402

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
(613) 421-8402

Tetra Bio-Pharma Inc.
André Audet
Executive Chairman
(613) 421-8402

 

Tags: , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Announces Outcome of its Meeting with its Scientific and Clinical Advisory Board $TBP.ca

Tetra Bio-Pharma Announces Acquisition of Intellectual Property for the Development of Natural Health Products Through Its Agro-Tek Subsidiary $TBP.ca

Posted by AGORACOM-JC at 8:35 AM on Wednesday, October 26th, 2016

Tbp_large

  • Announced that it has acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa
  • Recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content

OTTAWA, ONTARIO–(Oct. 26, 2016) – Tetra Bio-Pharma Inc. (“Tetra Bio” or the “Company“) (CSE:TBP)(CSE:TBP.CN), through its subsidiary, Agro-Tek Inc. (“AGTK“), is pleased to announce that it has acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa.

The recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content. According to the United States Food and Drug Administration (“FDA“), “FDA is not aware of any evidence that would call into question its current conclusion that cannabidiol products are excluded from the dietary supplement definition under section 201(f)(3)(B)(ii) of the Federal Food, Drug, & Cosmetics Act.”

Mr. André Rancourt, the Company’s CEO commented, “CBD or THC containing dietary supplements are currently not allowed on the USA market. However, the goal of the McGill University partnership is the development of extracts of the plant Cannabis sativa, including THC and CBD-free for the development of dietary supplements.” AGTK intends on manufacturing and commercializing supplements, food-type products and, natural health products that are compliant with Canadian and USA federal regulations. Mr. Rancourt added, “This commercial strategy involves the expertise of two of the Company’s subsidiaries, AGTK and MMP, and is in line with the Company’s vision to make AGTK and MMP leaders in the development of Cannabis sativa, derived products for the consumer market, and for the commercialization of natural supplements derived from Cannabis sativa.”

The assets acquired include proprietary formulations that have obtained marketing approval from Health Canada. The line consists of:

1. Glucose Aid; NPN 80058089

2. Kava Kava; NPN 80061986

3. Stress Ado; NPN 80065911

4. Toux Ado (Cough Ado); NPN 80065923

5. Toux enfant (Cough Children); NPN 80065928

6. Water Relax; NPN 80065948 (beverage supplement)

7. Water Cough; NPN 80066086 (beverage supplement)

8. Sleep Pro; NPN 80066679

9. Instant Relief; NPN 80066682 (topical gel for local pain relief).

The acquisition of these formulations and their proprietary ingredients will provide PhytoPain Pharma Inc. with an inventory of compounds and elements that will be used as secondary ingredients or catalysts in the formulation of our pharmaceutical grade products.

In consideration for the acquisition of the assets, the Company has issued 1,800,000 common shares to arms’ length individuals. The shares issued will be subject to a four-month hold period.

According to Mr. Rancourt, these products will allow AGTK to begin generating revenues. This is the first set of products for AGTK’s portfolio. The company will be seeking to acquire additional product lines for distribution in North America. AGTK is engaged in negotiations to acquire national distributors to expand brand identity and facilitate distribution across North America

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer

Ryan Brown
VP Business Development and Communications

Andre Audet
Executive Chairman
(613) 421-8402
[email protected]

Tags: , , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Announces Acquisition of Intellectual Property for the Development of Natural Health Products Through Its Agro-Tek Subsidiary $TBP.ca

« Older Entries
Newer Entries »